HER2-zero tumors had significantly more mutations in checkpoint factors (p < 0.01), Fanconi anemia (p < 0.05), and p53 signaling and cell cycle pathway (p < 0.05) than HER2-low breast tumors (Fig. 3F). Here, ERBB2 is linked to Fanconi anemia.